Pulmonary Alveolar Proteinosis and new therapeutic concepts

Author:

Rodriguez Gonzalez Claudio1,Schevel Hanna1,Hansen Gesine123,Schwerk Nicolaus12,Lachmann Nico1234

Affiliation:

1. Department for Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany

2. German Center for Lung Research (DZL), Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Hannover, Germany

3. Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, 30625 Hannover, Germany.

4. Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany

Abstract

AbstractPulmonary alveolar proteinosis (PAP) is an umbrella term used to refer to a pulmonary syndrome which is characterized by excessive accumulation of surfactant in the lungs of affected individuals. In general, PAP is a rare lung disease affecting children and adults, although its prevalence and incidence is variable among different countries. Even though PAP is a rare disease, it is a prime example on how modern medicine can lead to new therapeutic concepts, changing ways and techniques of (genetic) diagnosis which ultimately led into personalized treatments, all dedicated to improve the function of the impaired lung and thus life expectancy and quality of life in PAP patients. In fact, new technologies, such as new sequencing technologies, gene therapy approaches, new kind and sources of stem cells and completely new insights into the ontogeny of immune cells such as macrophages have increased our understanding in the onset and progression of PAP, which have paved the way for novel therapeutic concepts for PAP and beyond. As of today, classical monocyte-derived macrophages are known as important immune mediator and immune sentinels within the innate immunity. Furthermore, macrophages (known as tissue resident macrophages (TRMs)) can also be found in various tissues, introducing e. g. alveolar macrophages in the broncho-alveolar space as crucial cellular determinants in the onset of PAP and other lung disorders. Given recent insights into the onset of alveolar macrophages and knowledge about factors which impede their function, has led to the development of new therapies, which are applied in the context of PAP, with promising implications also for other diseases in which macrophages play an important role. Thus, we here summarize the latest insights into the various forms of PAP and introduce new pre-clinical work which is currently conducted in the framework of PAP, introducing new therapies for children and adults who still suffer from this severe, potentially life-threatening disease.

Publisher

Georg Thieme Verlag KG

Subject

Pediatrics, Perinatology and Child Health

Reference69 articles.

1. “Pulmonary Alveolar Proteinosis Syndrome,”;A Kelly;Semin Respir Crit Care Med,2020

2. “The role of lipids in pulmonary surfactant,”;R Veldhuizen;Biochim. Biophys. Acta - Mol. Basis Dis.,1998

3. “Surfactant granulocyte rnetabolism in transgenic mice after stimulating factor ablation,”;M Ikegami;Am J Physiol,1996

4. “Distinct changes in pulmonary surfactant homeostasis in common β-chain- and GM-CSF-deficient mice,”;J A Reed;Am. J. Physiol. - Lung Cell. Mol. Physiol.,2000

5. “Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan,”;Y Inoue;Am. J. Respir. Crit. Care Med.,2008

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3